breathing difficulty; Lung absess/infection; bronchitis; Sick for two weeks after second booster.; fever; explosive diarrhea; vomiting; severe fatigue/extreme fatigue; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP).  A 75-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 22Apr2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 75 years for covid-19 immunisation. The patient's relevant medical history included: "Coughing", start date: Dec2021 (unspecified if ongoing), notes: the patient reported coughing, fatigue and "chronic bronchitis" since Dec2021; "Fatigue", start date: Dec2021 (unspecified if ongoing); "Chronic bronchitis", start date: Dec2021 (unspecified if ongoing) and had no Known allergies at the time of vaccination. Concomitant medication(s) included: PNEUMOCOCCAL VACCINE, on 09Apr2022 as dose number unknown, single. Vaccination history included: BNT162b2 (DOSE 2, SINGLE), administration date: 22Apr2021, when the patient was 74-year-old, for COVID-19 immunization, reaction(s): "Fatigue"; BNT162b2 (DOSE 2, SINGLE), administration date: 22Apr2021, for COVID-19 immunization, reaction(s): "Body aches"; BNT162b2 (DOSE 2, SINGLE), administration date: 22Apr2021, for COVID-19 Immunization, reaction(s): "Flu like symptoms"; Bnt162b2 (DOSE 1, SINGLE), administration date: Apr2021, when the patient was 74 years old, for COVID-19 immunization; Covid-19 vaccine (DOSE 3, Manufacturer unknown), for COVID-19 immunization. The following information was reported: ILLNESS (non-serious) with onset 22Apr2022, outcome "recovered with sequelae", described as "Sick for two weeks after second booster."; DIARRHOEA (non-serious) with onset 22Apr2022, outcome "recovered with sequelae", described as "explosive diarrhea"; PYREXIA (non-serious) with onset 22Apr2022, outcome "recovered with sequelae", described as "fever"; FATIGUE (non-serious) with onset 22Apr2022, outcome "recovered with sequelae", described as "severe fatigue/extreme fatigue"; VOMITING (non-serious) with onset 22Apr2022, outcome "recovered with sequelae"; PNEUMONIA (medically significant), outcome "unknown", described as "Lung absess/infection"; DYSPNOEA (non-serious), outcome "unknown", described as "breathing difficulty"; BRONCHITIS (non-serious), outcome "unknown". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (14Jun2022) Negative, notes: Nasal Swab. Therapeutic measures were not taken as a result of illness, pyrexia, diarrhoea, vomiting, fatigue. Clinical course was reported as patient was sick for two weeks after second booster and had fever, explosive diarrhea, vomiting, and severe fatigue. Patient had self-reported (but not medically confirmed) and had bronchitis at the time of vaccination and diagnosed on 14Jun2022 with a lung absess/infection causing extreme fatigue and breathing difficulty. It was likely this infection was in place at the time of vaccination as the patient reported coughing, fatigue and chronic bronchitis since Dec2021. The patient had no covid Prior vaccination.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.